Skip to main content
Quest Diagnostics

Genetic Findings in a Cohort of Over 2,300 Individuals with Clinically Suspected Heritable Thoracic Aortic Disease

ESHG 2025

European Human Genetics Conference

Milan, Italy,  May 24-27, 2025

Poster presentation: Genetic Findings in a Cohort of Over 2,300 Individuals with Clinically Suspected Heritable Thoracic Aortic Disease

Authors: Mårtensson E, Hathaway J, Huusko J, Ahonen S, Tommiska J, Gall K, Djupsjöbacka J, Muona M, Saarinen I, Seppälä E, Kangas-Kontio T, Koskinen L, Salmenperä P, Myllykangas S, Koskenvuo J

Medical Specialty: Genetics, Cardiology, Cardiovascular disease

Disclaimer: One or more of the authors of this publication were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

On-Demand Webinar
Genetic testing in cardiovascular disease
Publication
Pharmacologic or Genetic Interference With Atrogene Signaling Protects Against Glucocorticoid-Induced Musculoskeletal and Cardiac Disease
Audio Podcast
Growing as a Laboratory Partner
Audio Podcast
The Cardiometabolic Approach: A Solution to Modern Disease Risk Assessment

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.